Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).

ABSTRACT: Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy, combining the antibody's exquisite specificity for the target antigen-expressing cancer cell together with the cytotoxic potency of the payload. Much success stems from the rational design of "toxic warheads", chemically linked to antibodies, and from fine-tuning the intricate properties of chemical linkers. Here, we focus on the antibody moiety of ADCs, dissecting the impact of Fab, linkers, isotype and Fc structure on the anti-tumoral and immune-activating functions of ADCs. Novel design approaches informed by antibody structural attributes present opportunities that may contribute to the success of next generation ADCs.

SUBMITTER: Hoffmann RM 

PROVIDER: S-EPMC5769674 | biostudies-literature |

REPOSITORIES: biostudies-literature